The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension

Raf kinases signal via extracellular signal-regulated kinases 1/2 (ERK1/2) to drive cell division. Since activating mutations in BRAF (B-Raf proto-oncogene, serine/threonine kinase) are highly oncogenic, BRAF inhibitors including dabrafenib have been developed for cancer. Inhibitors of ERK1/2 signal...

Descripción completa

Detalles Bibliográficos
Autores principales: Meijles, Daniel N., Cull, Joshua J., Cooper, Susanna T.E., Markou, Thomais, Hardyman, Michelle A., Fuller, Stephen J., Alharbi, Hajed O., Haines, Zoe H.R., Alcantara-Alonso, Viridiana, Glennon, Peter E., Sheppard, Mary N., Sugden, Peter H., Clerk, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2021
Materias:
Cardiovascular System & Vascular Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302807/
https://www.ncbi.nlm.nih.gov/pubmed/34296750
http://dx.doi.org/10.1042/CS20210192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302807/
https://www.ncbi.nlm.nih.gov/pubmed/34296750
http://dx.doi.org/10.1042/CS20210192

Ejemplares similares